Maiwei Biotechnology's (688062.SH) clinical trial application for injection 7MW4911 has been accepted.

Zhtng Cijng APP Xn, Miwi Shngw (688062.SH) gnggo, gngs shudo guji yopn jind gunl j (NMPA) qinf de "shul tngzhsh", zhsh yng 7MW4911 de lnchung shyn shnqng y hu zhngsh shul; cwi, gngs shudo migu shpn yopn jind gunl j (FDA) chj de IND Acknowledgement Letter, qurn y shudo gngs ji zhsh yng 7MW4911 dtu de IND shnqng. According to the news from the Wise Finance APP, Maiwei Biology (688062.SH) announced that the company has received the "Acceptance Notice" issued by the National Medical Products Administration (NMPA). The clinical trial application for injection 7MW4911 has been officially accepted. In addition, the company has received the IND Acknowledgement Letter issued by the Food and Drug Administration (FDA) of the United States, confirming the receipt of the company's IND application for injection 7MW4911.